Skip to main
ICLR
ICLR logo

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 25 analyst ratings
Buy
Strong Buy 32%
Buy 24%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Icon is positioned favorably within the rapidly expanding contract research organization (CRO) market, driven by long-term industry trends such as pharmaceutical vendor consolidation and increasing trial outsourcing. The company's strategic acquisition of PRA has enhanced its capabilities in early-phase trials and coupled with a robust service mix, allows it to navigate funding environment uncertainties effectively. Additionally, Icon's commitment to gender parity at senior levels reinforces its organizational strength, which, alongside anticipated growth in pharmaceutical R&D budgets, is likely to contribute positively to its revenue growth trajectory.

Bears say

Icon faces challenges stemming from a slower-than-anticipated recovery in the biotechnology sector, which is expected to adversely affect its revenue and growth trajectory in the near term. The negative sentiment is reinforced by a lack of impressive book-to-bill ratios, with the latest figures indicating potential difficulty in meeting investor expectations for growth in the upcoming quarters. Additionally, the company's anticipated earnings per share for 2025 show a concerning stagnation, suggesting that broader macroeconomic factors and client financial constraints could hinder its financial performance going forward.

ICON (ICLR) has been analyzed by 25 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 24% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 25 analysts, ICON (ICLR) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $197.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $197.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.